Lazaro Diaz, MD
Interventional Cardiology · Exeter, NHNPI 1164495230
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $12,935 of the $14,947 with a category attached, or 86.5%. 36 manufacturers reported payments, led by Penumbra, Inc. at 34.2% of the total. Reporting peaked in 2023 at $5,018 and has fallen 76.1% since, to $1,197 in 2025.
Across 243 payments — averaging $61.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Penumbra, Inc.$5K
- Inari Medical, Inc.$3K
- Boston Scientific$1K
- Medtronic$1K
- Abiomed$951
- Amgen$497
- plus $3K from 30 others
What the payments were for
- Travel & lodging$1,99413%
- Food & beverage$12,93587%
- Education$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Penumbra, Inc. | 28 | $5,106 |
| Inari Medical, Inc. | 45 | $3,183 |
| Boston Scientific | 12 | $1,215 |
| Medtronic(2 entities) | 12 | $1,104 |
| Abiomed | 16 | $951 |
| Amgen | 11 | $497 |
| Novartis | 20 | $309 |
| Boehringer Ingelheim | 9 | $295 |
| Alnylam Pharmaceuticals Inc. | 9 | $259 |
| Johnson & Johnson | 7 | $243 |
| Abbott | 5 | $213 |
| Shockwave Medical, Inc | 1 | $169 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 11 | $142 |
| Cvrx, Inc. | 1 | $141 |
| Stryker | 4 | $140 |
| Cardiovascular Systems Inc. | 9 | $114 |
| Actelion Pharmaceuticals US, Inc. | 6 | $111 |
| Pfizer | 6 | $98 |
| Daiichi Sankyo Inc. | 4 | $92 |
| Biotronik Inc. | 2 | $83 |
| E.r. Squibb & Sons, L.L.C. | 4 | $74 |
| Lexicon Pharmaceuticals, Inc. | 4 | $61 |
| Bayer | 3 | $48 |
| Sanofi-aventis U.S. LLC | 2 | $40 |
| Quidel Corporation | 1 | $34 |
| Regeneron Healthcare Solutions, Inc. | 1 | $26 |
| Atricure, Inc. | 1 | $26 |
| Kestra Medical Technology Services, Inc. | 1 | $25 |
| Merck | 1 | $24 |
| Portola Pharmaceuticals, LLC | 1 | $23 |
| Novo Nordisk | 1 | $20 |
| AstraZeneca | 1 | $18 |
| Lantheus Medical Imaging, Inc. | 1 | $18 |
| Vital Connect, Inc | 1 | $18 |
| Impulse Dynamics (USA) Inc. | 1 | $17 |
| Sensible Medical Innovations Inc | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FLOWTRIEVER CATHETER, S$2,169
- CT THROMBECTOMY SYSTEM KIT$2,169
- Indigo System$2,112
- Indigo$1,231
- RUBY Coil$1,154
- Watchman$671
- Impella$483
- Repatha$369
- ELUVIA$226
- HawkOne$178
- VenaSeal$174
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$169
- IN.PACT Admiral$148
- Barostim Neo System$141
- Smart Coil$140
- ONYX FRONTIER$140
- 3F$133
- GENERAL - STRUCTURAL HEART$117
- JARDIANCE$116
- Mitra Clip system$115
How this compares
$14,947 in reported general payments places this provider in the 70th percentile of 26 interventional cardiology providers in New Hampshire.
See all interventional cardiology providers in New Hampshire →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 158 | $156,606 |
| XareltoRivaroxaban | 118 | $148,510 |
| EntrestoSacubitril/Valsartan | 43 | $48,458 |
| JardianceEmpagliflozin | 42 | $45,387 |
| Ambrisentan | 14 | $39,656 |
| OzempicSemaglutide | 19 | $17,878 |
| Repatha SureclickEvolocumab | 13 | $14,941 |
| Repatha SyringeEvolocumab | 13 | $14,219 |
| FarxigaDapagliflozin Propanediol | 15 | $11,943 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 29 | $8,124 |
| BrilintaTicagrelor | 12 | $7,929 |
| Dofetilide | 17 | $3,143 |
| Metoprolol Succinate | 218 | $2,642 |
| Amiodarone Hcl | 78 | $2,367 |
| ClopidogrelClopidogrel Bisulfate | 190 | $1,785 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $98 | $156,606158 claims |
| Johnson & JohnsonXarelto | $243 | $148,510118 claims |
| NovartisEntresto | $309 | $48,45843 claims |
| Boehringer IngelheimJardiance | $295 | $45,38742 claims |
| AstraZenecaFarxiga, Brilinta | $18 | $19,87127 claims |
| Novo NordiskOzempic | $20 | $17,87819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 26 interventional cardiology providers in New Hampshire.
Other interventional cardiology in Exeter
- Joshua KrasnowExeter$6K
- Jessica SutherlandExeter$2K
- Shahab MoossaviConcord$36K
- Nitish SharmaDover$23K
- Rodrigo Mendirichaga MaganaDover$21K
- Hannah ChaudryLebanon$20K
- Eric RothsteinLebanon$20K
- James DevriesLebanon$19K
- Xiaoyu Yang-GiulianoManchester$18K
- Aaron KaplanLebanon$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.